These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 6655288)

  • 21. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers.
    Bhamarapravati N; Yoksan S; Chayaniyayothin T; Angsubphakorn S; Bunyaratvej A
    Bull World Health Organ; 1987; 65(2):189-95. PubMed ID: 3496985
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of viraemia and limited antibody response of dengue virus immune rhesus monkeys after vaccination with DEN-2/S-1 vaccine.
    Kraiselburd E; Kessler MJ; Torres-Blasini G
    Trans R Soc Trop Med Hyg; 1984; 78(4):445-8. PubMed ID: 6548325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antibody responses in Japanese volunteers after immunization with yellow fever vaccine].
    Taga K; Imura S; Hayashi A; Kamakura K; Hashimoto S; Takasaki T; Kurane I; Uchida Y
    Kansenshogaku Zasshi; 2002 Sep; 76(9):738-46. PubMed ID: 12391677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys.
    Galler R; Marchevsky RS; Caride E; Almeida LF; Yamamura AM; Jabor AV; Motta MC; Bonaldo MC; Coutinho ES; Freire MS
    Braz J Med Biol Res; 2005 Dec; 38(12):1835-46. PubMed ID: 16302098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles.
    Lindow JC; Durbin AP; Whitehead SS; Pierce KK; Carmolli MP; Kirkpatrick BD
    Vaccine; 2013 Jul; 31(33):3347-52. PubMed ID: 23735680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood value changes in flavivirus-inoculated Macaca fascicularis monkeys.
    Angsubhakorn S; Yoksan S; Henchal EA; Nisalak A; Hoke CH; Pradermwong A; Sahaphong S; Bhamarapravati N
    Southeast Asian J Trop Med Public Health; 1986 Mar; 17(1):1-7. PubMed ID: 2874612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates.
    Sun W; Edelman R; Kanesa-Thasan N; Eckels KH; Putnak JR; King AD; Houng HS; Tang D; Scherer JM; Hoke CH; Innis BL
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):24-31. PubMed ID: 14740952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Arboviruses and lemurs in Madagascar: experimental infection of Lemur fulvus with attenuated strains of yellow fever virus].
    Rodhain F
    Bull Soc Pathol Exot Filiales; 1984; 77(3):255-62. PubMed ID: 6488418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of chloroquine prophylaxis on yellow fever vaccine antibody response: comparison of plaque reduction neutralization test and enzyme-linked immunosorbent assay.
    Barry M; Patterson JE; Tirrell S; Cullen MR; Shope RE
    Am J Trop Med Hyg; 1991 Jan; 44(1):79-82. PubMed ID: 1996743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes.
    Putnak R; Fuller J; VanderZanden L; Innis BL; Vaughn DW
    Am J Trop Med Hyg; 2003 Apr; 68(4):469-76. PubMed ID: 12875299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region.
    Durbin AP; Karron RA; Sun W; Vaughn DW; Reynolds MJ; Perreault JR; Thumar B; Men R; Lai CJ; Elkins WR; Chanock RM; Murphy BR; Whitehead SS
    Am J Trop Med Hyg; 2001 Nov; 65(5):405-13. PubMed ID: 11716091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MAC-ELISA and ELISA inhibition methods for detection of antibodies after yellow fever vaccination.
    Vázquez S; Valdés O; Pupo M; Delgado I; Alvarez M; Pelegrino JL; Guzmán MG
    J Virol Methods; 2003 Jun; 110(2):179-84. PubMed ID: 12798246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers.
    Durbin AP; Whitehead SS; McArthur J; Perreault JR; Blaney JE; Thumar B; Murphy BR; Karron RA
    J Infect Dis; 2005 Mar; 191(5):710-8. PubMed ID: 15688284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody response to dengue-2 vaccine measured by two different radioimmunoassay methods.
    Summers PL; Eckels KH; Dalrymple JM; Scott RM; Boyd VA
    J Clin Microbiol; 1984 May; 19(5):651-9. PubMed ID: 6330164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The standardization of the plaque reduction technic for differentiating a dengue infection from a yellow fever infection].
    Alvarez Vera M; Valdés Palacios D; Vázquez Ramudo S; Delgado Hernández I; García Infante S; Morier Díaz L; Guzmán Tirado MG
    Rev Cubana Med Trop; 1998; 50(3):177-81. PubMed ID: 10349439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Research on dengue in tissue culture. IV. Serologic responses of human beings to combined inoculations of attenuated, tissue-cultured type I dengue virus and yellow fever vaccine.
    Fujita N; Oda K; Yasui Y; Hotta S
    Kobe J Med Sci; 1969 Dec; 15(4):163-80. PubMed ID: 4317037
    [No Abstract]   [Full Text] [Related]  

  • 38. Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys.
    Angsubhakorn S; Yoksan S; Bhamarapravati N; Moe JB; Marchette NJ; Pradermwong A; Sahaphong S
    Trans R Soc Trop Med Hyg; 1988; 82(5):746-9. PubMed ID: 3252595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys.
    Kochel TJ; Raviprakash K; Hayes CG; Watts DM; Russell KL; Gozalo AS; Phillips IA; Ewing DF; Murphy GS; Porter KR
    Vaccine; 2000 Jul; 18(27):3166-73. PubMed ID: 10856796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
    Guirakhoo F; Pugachev K; Zhang Z; Myers G; Levenbook I; Draper K; Lang J; Ocran S; Mitchell F; Parsons M; Brown N; Brandler S; Fournier C; Barrere B; Rizvi F; Travassos A; Nichols R; Trent D; Monath T
    J Virol; 2004 May; 78(9):4761-75. PubMed ID: 15078958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.